Citing current market conditions, Inveresk Research Group said this morning that it plans to withdraw its proposed public offering of up to 10.3 million shares.

Inveresk, a provider of drug development services, had filed its intentions with the SEC on Feb. 18. “The company believes that current market conditions make it inadvisable to proceed with the offering at this time,” Iveresk said in a statement.